Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid in Chondrosarcoma
NCT03173976Phase 1Active, not recruiting
- Start
- Jul 2017
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial of zoledronic acid in chondrosarcoma. Primary endpoint: Dose Limiting Toxicity. Started Jul 2017; status: active, not recruiting.
02
Drugs
zoledronic acid
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on NCT03173976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173976.